GYRE (Gyre Therapeutics) Total Stockholders Equity : $68.1 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Total Stockholders Equity?

Gyre Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $68.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Gyre Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was $0.78. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Gyre Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.02.

Gyre Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Gyre Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Total Stockholders Equity Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

72.92

42.52

-15.83

63.32

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial							56.64	60.35	63.18	63.32	68.12

Gyre Therapeutics (NAS:GYRE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Gyre Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(68.123	-	0)	/	87.636
	=	0.78

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Gyre Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.805	+	0.78)	/	68.123
	=	0.02

Gyre Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.